Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes

AIMS/INTRODUCTION: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are used worldwide because of their multiple benefits for patients with type 2 diabetes. The purpose of this study was to determine the efficacy and safety of SGLT2i in patients with type 1 diabetes. MATERIALS AND METHODS: Patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiba, Koki, Nomoto, Hiroshi, Nakamura, Akinobu, Cho, Kyu Yong, Yamashita, Kumiko, Shibayama, Yui, Miya, Aika, Kameda, Hiraku, Kurihara, Yoshio, Aoki, Shin, Atsumi, Tatsuya, Miyoshi, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858126/
https://www.ncbi.nlm.nih.gov/pubmed/32593203
http://dx.doi.org/10.1111/jdi.13335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858126/
https://www.ncbi.nlm.nih.gov/pubmed/32593203
http://dx.doi.org/10.1111/jdi.13335

Ejemplares similares